Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients across New Mexico — from Agua Fria to smaller communities — are achieving documented weight reduction with FDA-approved peptide medications through licensed telehealth. The Peptide Protocol establishes a structured pathway: physician evaluation, evidence-based peptide selection, systematic dose titration, and regular monitoring. NM-licensed physicians guide every stage of your protocol.
Licensed physicians in our network prescribe semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) following the evidence-based dose-escalation schedules established in the STEP 1 and SURMOUNT-1 randomized controlled trials published in the New England Journal of Medicine.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
New Mexico patients access The Peptide Protocol entirely online. All physicians hold active NM medical licenses and follow evidence-based titration protocols established in phase III clinical trials. Your protocol begins with a comprehensive evaluation and continues with scheduled check-ins.
Select your New Mexico city to begin the Peptide Protocol. Licensed physicians are serving patients in every corner of the state.
The following landmark trials published in the New England Journal of Medicine establish the efficacy and safety profile of FDA-approved GLP-1 medications:
New Mexico authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in New Mexico.
The Peptide Protocol extends beyond New Mexico — structured peptide therapy is available in all neighboring states and all 50 states nationwide.
FDA-approved GLP-1 prescriptions are accessible from any city through our board-certified telehealth network. Find your city below to get started.
Local weight loss and GLP-1 providers serving the New Mexico area, based on Google Business listings.
4001 Juan Tabo Blvd NE A, Albuquerque, NM 87111
(505) 888-9575
4.8/5 ★ (201 reviews)
Visit website →4919 Prospect Ave NE, Albuquerque, NM 87110
(505) 888-0797
5/5 ★ (89 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
New Mexico patients on The Peptide Protocol have access to semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — all FDA-approved peptide receptor agonists. Your NM-licensed physician selects the optimal peptide agent based on your health profile, goals, and any existing conditions.
Most New Mexico protocol patients notice appetite reduction within the first 1-2 weeks. Measurable weight reduction typically begins in weeks 2-4. Results accelerate as the structured dose escalation progresses. Most significant changes occur in months 3-6, consistent with clinical trial timelines.
Yes. The Peptide Protocol is available to patients across all of New Mexico through licensed telehealth. All prescribing physicians hold active NM state medical licenses. Whether you are in a major metropolitan area or a smaller community, the same structured protocol is accessible.
GLP-1 receptor agonists improve multiple metabolic markers beyond body weight. The SELECT trial (NEJM 2023) confirmed a 20% reduction in major cardiovascular events with semaglutide in adults with established CVD — making GLP-1 therapy particularly valuable for patients with metabolic syndrome or type 2 diabetes.
The initial Peptide Protocol for New Mexico patients typically spans 68-72 weeks — the same duration used in the landmark clinical trials. After completing the initial protocol, NM physicians work with patients on maintenance strategies to preserve their results. Long-term, many patients continue on a maintenance dose protocol.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
